Regenxbio outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
Curran Simpson, President and CEO, stated, "2026 is set to be a pivotal year for REGENXBIO with great focus on advancing our late-stage pipeline in 2025," emphasizing near-term top line Phase III readouts and Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights REGENXBIO faces clinical holds and a CRL for RGX-111 and RGX-121, but management believes the requirements to remove these holds are addressable. Clinical data show meaningful differentiation and a favorable safety profile, with no serious adverse events or immune-related issues reported. The company has $241 million in cash, expects cash to fund operations into early 2027, and may extend this with milestones or royalty monetization. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- REGENXBIO (RGNX) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNXPR Newswire
- ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNXGlobeNewswire
- RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLSTPR Newswire
RGNX
Earnings
- 3/5/26 - Miss
RGNX
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/12/26 - Form 424B5
- RGNX's page on the SEC website